Search Results - "CLANET, M"

ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis by Montalban, X., Gold, R., Thompson, A. J., Otero‐Romero, S., Amato, M. P., Chandraratna, D., Clanet, M., Comi, G., Derfuss, T., Fazekas, F., Hartung, H. P., Havrdova, E., Hemmer, B., Kappos, L., Liblau, R., Lubetzki, C., Marcus, E., Miller, D. H., Olsson, T., Pilling, S., Selmaj, K., Siva, A., Sorensen, P. S., Sormani, M. P., Thalheim, C., Wiendl, H., Zipp, F.

“…Background and purpose Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is therefore a need for a…”
Get full text

EFNS guidelines on diagnosis and management of neuromyelitis optica by Sellner, J., Boggild, M., Clanet, M., Hintzen, R. Q., Illes, Z., Montalban, X., Du Pasquier, R. A., Polman, C. H., Sorensen, P. S., Hemmer, B.

“…Background and purpose:  Neuromyelitis optica (NMO) or Devic′s disease is a rare inflammatory and demyelinating autoimmune disorder of the central nervous…”
Get full text

Modafinil for fatigue in MS : A randomized placebo-controlled double-blind study by STANKOFF, B, WAUBANT, E, CONFAVREUX, C, EDAN, G, DEBOUVERIE, M, RUMBACH, L, MOREAU, T, PELLETIER, J, LUBETZKI, C, CLANET, M

“…To assess whether modafinil, a wakefulness-promoting agent, is useful for fatigue in patients with multiple sclerosis (MS). Patients with MS with stable…”
Get full text

Mutations within the Programmed Cell Death 10 Gene Cause Cerebral Cavernous Malformations by Bergametti, F., Denier, C., Labauge, P., Arnoult, M., Boetto, S., Clanet, M., Coubes, P., Echenne, B., Ibrahim, R., Irthum, B., Jacquet, G., Lonjon, M., Moreau, J.J., Neau, J.P., Parker, F., Tremoulet, M., Tournier-Lasserve, E.

“…Cerebral cavernous malformations (CCMs) are hamartomatous vascular malformations characterized by abnormally enlarged capillary cavities without intervening…”
Get full text

Neuromyelitis optica in France: A multicenter study of 125 patients by COLLONGUES, N, MARIGNIER, R, FONTAINE, B, BRASSAT, D, CLANET, M, MILH, M, PELLETIER, J, AUDOIN, B, RUET, A, LEBRUN-FRENAY, C, THOUVENOT, E, CAMU, W, ZEPHIR, H, DEBOUVERIE, M, CREANGE, A, MOREAU, T, LABAUGE, P, CASTELNOVO, G, EDAN, G, LE PAGE, E, DEFER, G, BARROSO, B, HEINZLEF, O, PAPEIX, C, GOUT, O, RODRIGUEZ, D, WIERTLEWSKI, S, LAPLAUD, D, BORGEL, F, TOURNIAIRE, P, GRIMAUD, J, BROCHET, B, VERMERSCH, P, CONFAVREUX, C, BLANC, F, DE SEZE, J, RITLENG, C, TCHIKVILADZE, M, OUTTERYCK, O, VUKUSIC, S, FLEURY, M

“…There have been few epidemiologic studies on neuromyelitis optica (NMO) and none used the recent 2006 diagnostic criteria. Here we describe the clinical,…”
Get full text

Jean-Martin Charcot. 1825 to 1893 by Clanet, M

“…During the 31 years of his working life, Jean-Martin Charcot built up an exceptional career in Salpétrière hospital, and was a pioneer in different fields. He…”
Get more information

Neutralizing antibodies and efficacy of interferon β-1a : A 4-year controlled study by KAPPOS, L, CLANET, M, SANDBERG-WOLLHEIM, M, RADUE, E. W, HARTUNG, H. P, HOHLFELD, R, XU, J, BENNETT, D, SANDROCK, A, GOELZ, S

Get full text

Peripheral late reactivation of a previously typical monofocal Baló’s concentric sclerosis lesion by Pique, J, Bonneville, F, Brassat, D, Peaureaux, D, Benaiteau, M, Dumas, H, Fabre, N, Clanet, M, Biotti, D

“…We report a 41-year-old woman with rapidly progressive left hemiparesis, revealing an inflammatory reactivation of a previously known parietal Baló’s…”
Get full text

Rate of brain atrophy in relapsing MS decreases during treatment with IFNβ-1a by HARDMEIER, M, WAGENPFEIL, S, FREITAG, P, FISHER, E, RUDICK, R. A, KOOIJMANS, M, CLANET, M, RADUE, E. W, KAPPOS, L

Get full text

A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort by Outteryck, O., Ongagna, J.C., Brochet, B., Rumbach, L., Lebrun-Frenay, C., Debouverie, M., Zéphir, H., Ouallet, J.C., Berger, E., Cohen, M., Pittion, S., Laplaud, D., Wiertlewski, S., Cabre, P., Pelletier, J., Rico, A., Defer, G., Derache, N., Camu, W., Thouvenot, E., Moreau, T., Fromont, A., Tourbah, A., Labauge, P., Castelnovo, G., Clavelou, P., Casez, O., Hautecoeur, P., Papeix, C., Lubetzki, C., Fontaine, B., Couturier, N., Bohossian, N., Clanet, M., Vermersch, P., de Sèze, J., Brassat, D.

“…Background and purpose BIONAT is a French multicentric phase IV study of natalizumab (NTZ)‐treated relapsing−remitting multiple sclerosis (MS) patients. The…”
Get full text

IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations by Weber, F, Fontaine, B, Cournu-Rebeix, I, Kroner, A, Knop, M, Lutz, S, Müller-Sarnowski, F, Uhr, M, Bettecken, T, Kohli, M, Ripke, S, Ising, M, Rieckmann, P, Brassat, D, Semana, G, Babron, M-C, Mrejen, S, Gout, C, Lyon-Caen, O, Yaouanq, J, Edan, G, Clanet, M, Holsboer, F, Clerget-Darpoux, F, Müller-Myhsok, B

“…Multiple sclerosis (MS) is the most common chronic inflammatory neurologic disorder diagnosed in young adults and, due to its chronic course, is responsible…”
Get full text

Address from the previous president, January 13, 2012 by Clanet, M

Get full text

Impact of intermittent catheterization on the quality of life of multiple sclerosis patients by Castel-Lacanal, E., Gamé, X., De Boissezon, X., Guillotreau, J., Braley-Berthoumieux, E., Terracol, C., Gasq, D., Labrunee, M., Viala, F., Rischmann, P., Clanet, M., Marque, P.

“…Purpose Lower urinary tract dysfunction is common in multiple sclerosis (MS). The purpose of this study was to prospectively evaluate the impact of…”
Get full text

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment by Polman, C H, Reingold, S C, Barkhof, F, Calabresi, P A, Clanet, M, Cohen, J A, Cutter, G R, Freedman, M S, Kappos, L, Lublin, F D, McFarland, H F, Metz, L M, Miller, A E, Montalban, X, O'Connor, P W, Panitch, H, Richert, J R, Petkau, J, Schwid, S R, Sormani, M P, Thompson, A J, Weinshenker, B G, Wolinsky, J S

“…The increasing number of established effective therapies for relapsing multiple sclerosis (MS) and emerging consensus for early treatment raise practical…”
Get full text

Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS by BRASSAT, D, RECHER, C, WAUBANT, E, LE PAGE, E, RIGAL-HUGUET, F, LAURENT, G, EDAN, G, CLANET, M

“…The authors report a patient with severe secondary progressive MS who responded to mitoxantrone but developed a fatal acute myeloblastic leukemia 15 months…”
Get full text

MULTIPLE DURAL LESIONS MIMICKING MENINGIOMAS IN PATIENTS WITH CCM3/ PDCD10 MUTATIONS by LABAUGE, P, FONTAINE, B, OLSCHWANG, S, DENIER, C, TOURNIER-LASSERVE, E, NEAU, J.-P, BERGAMETTI, F, RIANT, F, BLECON, A, MARCHELLI, F, ARNOULT, M, LANNUZEL, A, CLANET, M

Get full text

Gender effects on intramuscular interferon beta-1a in relapsing–remitting multiple sclerosis: analysis of 1406 patients by Rudick, RA, Kappos, L, Kinkel, R, Clanet, M, Phillips, JT, Herndon, RM, Sandrock, AW, Munschauer, FE

“…Background: We aimed to evaluate effects of gender on efficacy and safety of intramuscular (IM) interferon beta (IFNβ)-1a in patients with relapsing–remitting…”
Get full text

Cerebrotendinous xanthomatosis: a multicentric retrospective study of 15 adults, clinical and paraclinical typical and atypical aspects by Lionnet, C, Carra, C, Ayrignac, X, Levade, T, Gayraud, D, Castelnovo, G, Besson, G, Androdias, G, Vukusic, S, Confavreux, C, Zaenker, C, De Seze, J, Collongues, N, Blanc, F, Tranchant, C, Wallon, D, Hannequin, D, Gerdelat-Mas, A, Brassat, D, Clanet, M, Zephir, H, Outteryck, O, Vermersch, P, Labauge, P

“…Cerebrotendinous xanthomatosis, a metabolic leukodystrophy with an autosomal recessive inheritance, is secondary to deficiency of sterol 27-hydroxylase, an…”
Get full text

Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis by Petzold, A, Brassat, D, Mas, P, Rejdak, K, Keir, G, Giovannoni, G, Thompson, E J, Clanet, M.

“…Background: This study aimed to investigate if treatment response could retrospectively be related to inflammatory or axonal patho logy as measured by plasma…”
Get full text

A Second-Generation Genomic Screen for Multiple Sclerosis by Kenealy, S.J., Babron, M.-C., Bradford, Y., Schnetz-Boutaud, N., Haines, J.L., Rimmler, J.B., Schmidt, S., Pericak-Vance, M.A., Barcellos, L.F., Lincoln, R.R., Oksenberg, J.R., Hauser, S.L., Clanet, M., Brassat, D., Edan, G., Yaouanq, J., Semana, G., Cournu-Rebeix, I., Lyon-Caen, O., Fontaine, B.

“…Multiple sclerosis (MS) is a debilitating neuroimmunological and neurodegenerative disorder. Despite substantial evidence for polygenic inheritance of the…”
Get full text